GW 468816 is glycine receptor antagonist. It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.
Investigated for use/treatment in tobacco dependence.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.